Brokers Offer Predictions for Amgen Inc.’s Q2 2025 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Research analysts at Zacks Research lowered their Q2 2025 earnings estimates for shares of Amgen in a report released on Tuesday, June 25th. Zacks Research analyst S. Ganoria now forecasts that the medical research company will post earnings per share of $5.05 for the quarter, down from their prior estimate of $5.07. The consensus estimate for Amgen’s current full-year earnings is $19.47 per share. Zacks Research also issued estimates for Amgen’s Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.45 EPS and FY2025 earnings at $20.48 EPS.

Several other equities analysts also recently issued reports on AMGN. Truist Financial reissued a “buy” rating and set a $320.00 price target on shares of Amgen in a report on Friday, April 12th. William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Royal Bank of Canada increased their price objective on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Finally, TD Cowen reduced their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average price target of $305.85.

Amgen Trading Down 2.0 %

NASDAQ:AMGN opened at $312.82 on Thursday. The firm has a market capitalization of $167.81 billion, a P/E ratio of 44.69, a P/E/G ratio of 2.88 and a beta of 0.60. The business has a 50 day simple moving average of $298.70 and a 200 day simple moving average of $291.52. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. Amgen has a 12-month low of $218.44 and a 12-month high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter in the previous year, the business posted $3.98 EPS. The firm’s revenue was up 22.0% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BIP Wealth LLC grew its stake in Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 32 shares in the last quarter. RFP Financial Group LLC grew its position in Amgen by 17.1% in the first quarter. RFP Financial Group LLC now owns 219 shares of the medical research company’s stock worth $62,000 after acquiring an additional 32 shares in the last quarter. Southland Equity Partners LLC increased its stake in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after purchasing an additional 34 shares during the last quarter. Acropolis Investment Management LLC raised its holdings in shares of Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after purchasing an additional 34 shares in the last quarter. Finally, Opal Wealth Advisors LLC lifted its stake in shares of Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 34 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.